Literature DB >> 26388239

Inhibition of squamous cancer growth in a mouse model by Staphylococcal enterotoxin B-triggered Th9 cell expansion.

Bei-Ping Miao1,2, Rui-Shi Zhang1, Huan-Ji Sun1, Yan-Ping Yu1, Tao Chen1, Lin-Jing Li3, Jiang-Qi Liu3, Jun Liu4, Hai-Qiong Yu2, Min Zhang5, Zhi-Gang Liu2, Ping-Chang Yang2.   

Abstract

Currently, therapy for squamous cancer (SqC) is unsatisfactory. Staphylococcal enterotoxin B (SEB) has strong immune regulatory activity. This study tests the hypothesis that SEB enforces the effect of immunotherapy on SqC growth in a mouse model. C3H/HeN mice and the SqC cell line squamous cell carcinoma VII were used to create an SqC mouse model. Immune cell assessment was performed by flow cytometry. Real-time RT-PCR and western blotting were used to evaluate target molecule expression. An apoptosis assay was used to assess the suppressive effect of T helper-9 (Th9) cells on the SqC cells. The results showed that immunotherapy consisting of SEB plus SqC antigen significantly inhibited SqC growth in the mice. The frequency of Th9 cells was markedly increased in the SqC tissue and mouse spleens after treatment. SEB markedly increased the levels of signal transducer and activator of transcription 5 phosphorylation and the expression of histone deacetylase-1 (HDAC1) and PU.1 (the transcription factor of the interleukin 9 (IL-9) gene) in CD4+ T cells. Exposure to SqC-specific Th9 cells markedly induced SqC cell apoptosis both in vitro and in vivo. In conclusion, the administration of SEB induces Th9 cells in SqC-bearing mice, and theseTh9 cells inhibit SqC growth.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26388239      PMCID: PMC5380942          DOI: 10.1038/cmi.2015.88

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  28 in total

Review 1.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

Review 2.  Th9 cells: a novel CD4 T-cell subset in the immune war against cancer.

Authors:  Frédérique Végran; Lionel Apetoh; François Ghiringhelli
Journal:  Cancer Res       Date:  2015-01-14       Impact factor: 12.701

3.  Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.

Authors:  Peng Zhao; Xiaocui Bu; Xiaofang Wei; Weihong Sun; Xihe Xie; Changyou Li; Qingming Guo; Danni Zhu; Xiaoqiang Wei; Daiqing Gao
Journal:  Int Immunopharmacol       Date:  2015-02-16       Impact factor: 4.932

Review 4.  Non coding RNAs in head and neck squamous cell carcinoma (HNSCC): a clinical perspective.

Authors:  Nerina Denaro; Marco Carlo Merlano; Elvio Grazioso Russi; Cristiana Lo Nigro
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

5.  Lymph node metastasis in t4 maxillary sinus squamous cell carcinoma: incidence and treatment outcome.

Authors:  Akihiro Homma; Ryuichi Hayashi; Kazuto Matsuura; Kengo Kato; Kazuyoshi Kawabata; Nobuya Monden; Yasuhisa Hasegawa; Tetsuro Onitsuka; Yasushi Fujimoto; Shigemichi Iwae; Kenji Okami; Takashi Matsuzuka; Kunitoshi Yoshino; Ken-Ichi Nibu; Takakuni Kato; Hiroshi Nishino; Takahiro Asakage; Ichiro Ota; Morimasa Kitamura; Akira Kubota; Tsutomu Ueda; Kaichiro Ikebuchi; Akihito Watanabe; Masato Fujii
Journal:  Ann Surg Oncol       Date:  2014-02-20       Impact factor: 5.344

6.  The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Authors:  Frédérique Végran; Hélène Berger; Romain Boidot; Grégoire Mignot; Mélanie Bruchard; Magalie Dosset; Fanny Chalmin; Cédric Rébé; Valentin Dérangère; Bernhard Ryffel; Masashi Kato; Armelle Prévost-Blondel; François Ghiringhelli; Lionel Apetoh
Journal:  Nat Immunol       Date:  2014-06-29       Impact factor: 25.606

7.  Sinonasal malignancy: presentation and outcomes.

Authors:  Y B Mahalingappa; H S Khalil
Journal:  J Laryngol Otol       Date:  2014-07       Impact factor: 1.469

8.  Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.

Authors:  Rahul Purwar; Christoph Schlapbach; Sheng Xiao; Hong Soon Kang; Wassim Elyaman; Xiaodong Jiang; Anton M Jetten; Samia J Khoury; Robert C Fuhlbrigge; Vijay K Kuchroo; Rachael A Clark; Thomas S Kupper
Journal:  Nat Med       Date:  2012-07-08       Impact factor: 53.440

9.  IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.

Authors:  Valérie Dardalhon; Amit Awasthi; Hyoung Kwon; George Galileos; Wenda Gao; Raymond A Sobel; Meike Mitsdoerffer; Terry B Strom; Wassim Elyaman; I-Cheng Ho; Samia Khoury; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

10.  Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma.

Authors:  Rahim Farahani; Roya Sherkat; Mazdak Ganjalikhani Hakemi; Nahid Eskandari; Reza Yazdani
Journal:  Adv Biomed Res       Date:  2014-05-28
View more
  10 in total

1.  Human Vδ2 T cells are a major source of interleukin-9.

Authors:  Christian Peters; Robert Häsler; Daniela Wesch; Dieter Kabelitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

2.  TGF-β enhances the cytotoxic activity of Vδ2 T cells.

Authors:  Christian Peters; Annika Meyer; Léonce Kouakanou; Julia Feder; Tim Schricker; Marcus Lettau; Ottmar Janssen; Daniela Wesch; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

3.  Targeting the IL-9 pathway in cancer immunotherapy.

Authors:  Ningbo Zheng; Yong Lu
Journal:  Hum Vaccin Immunother       Date:  2020-02-10       Impact factor: 3.452

4.  [Expression of interleukin-9 in colon cancer tissues and its clinical significance].

Authors:  Jin Wang; Xiaoqiang Dong; Xinguo Zhu; Hua Zhao; Deli Mao; Xin Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

Review 5.  TH9 cells in anti-tumor immunity.

Authors:  Thaiz Rivera Vargas; Etienne Humblin; Frédérique Végran; François Ghiringhelli; Lionel Apetoh
Journal:  Semin Immunopathol       Date:  2016-11-10       Impact factor: 9.623

Review 6.  Th9 Cell Differentiation and Its Dual Effects in Tumor Development.

Authors:  Tao Chen; Jufeng Guo; Zhenhai Cai; Binghao Li; Lingling Sun; Yingying Shen; Shengdong Wang; Zhan Wang; Zenan Wang; Yucheng Wang; Hao Zhou; Zhijian Cai; Zhaoming Ye
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

7.  IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment In Vivo.

Authors:  Jin Wang; Mingbing Sun; Hua Zhao; Yang Huang; Dongbao Li; Deli Mao; Zhe Zhang; Xinguo Zhu; Xiaoqiang Dong; Xin Zhao
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

8.  Expression and clinical significance of interleukin-9 in renal tumors.

Authors:  Zhiyu Zhang; Qi Zhou; Jun Ouyang; Jinxian Pu; Jianquan Hou; Jianglei Zhang
Journal:  Transl Androl Urol       Date:  2020-12

Review 9.  New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries.

Authors:  Tejeshwar Jain; Prateek Sharma; Abhi C Are; Selwyn M Vickers; Vikas Dudeja
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

Review 10.  IL-9 and IL-9-producing cells in tumor immunity.

Authors:  Jie Wan; Yinqiu Wu; Xiaoyun Ji; Lan Huang; Wei Cai; Zhaoliang Su; Shengjun Wang; Huaxi Xu
Journal:  Cell Commun Signal       Date:  2020-03-30       Impact factor: 5.712

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.